



2014 IMPACT REPORT

Pediatric Initiatives

4,000 children are diagnosed with a brain tumor each year. ■ Brain tumors are the leading cause of cancer-related death in children under the age of 14. ■ Brain tumors cannot be prevented and no cure exists today. ■ Current treatment options are limited and can provide damaging long-term side effects to a child's developing brain. ■ The average survival rate for all children with malignant brain tumors is 66%.



Brain tumors are the leading cause of cancer-related death in children under the age of 14. Moreover, current pediatric treatment options are quite limited and can provide damaging long-term side effects to a child's developing brain. This is unacceptable.

National Brain Tumor Society is fiercely committed to finding better treatments, and ultimately a cure, for those living with a brain tumor today and those who will be diagnosed tomorrow. This means effecting change in the systems at all levels.

To improve the lives of pediatric patients, the National Brain Tumor Society is working to create a better system to discover, develop, test, and evaluate potential brain tumor treatments. Ultimately allowing groundbreaking discoveries to rapidly move from the laboratory and into the hands of patients.

This critical work relies on the generosity and dedication of philanthropic partners like you.

PARTNER FOR PROGRESS

Through your generous support, the National Brain Tumor Society has been able to:

- Complete an initiative in the molecular profiling of pediatric brain tumors, which allows future researchers to better understand the underlying biology that is driving these cancers.
- Complete an initiative in developmental neurobiology to better understand the relationship between pediatric brain tumors and a child's developing brain, and how best to protect it from the toxicity of treatment.
- Launch **Project Impact**, a major new effort to battle potentially difficult pediatric brain tumors and address the most critical barriers hindering drug development.
- Champion pediatric brain tumor legislation in the United States Congress that is providing more funding for pediatric research and drug development.



“National Brain Tumor Society has played a critical role in the development of research programs in brain tumors generally, as well as in pediatrics.”

– Dr. Scott Pomeroy, MD, PhD

OUR COMMITMENT TO PEDIATRICS

Building on the knowledge gained through the earlier work in molecular profiling and developmental neurobiology, the National Brain Tumor Society will fund leading science, develop the right structure to support this science, foster collaboration to quicken discovery, and optimize the clinical trial process. Further support from individuals and organizations will allow us to provide more treatments to patients and doctors. Since our inception, the National Brain Tumor Society has funded more than \$30 million in research, of which 22% has been for pediatrics and 68% for adults.

CURRENT PROGRAMS OF IMPACT


Project Impact: Driving Discovery to a Cure for Pediatrics is a multi-faceted initiative that was announced in March of 2014. The primary goal of Project Impact is to address the key interrelated barriers that are slowing drug development for pediatric brain tumors. This initiative will combine efforts in funded research and public policy to confront inefficiencies that currently exist in the pre-clinical and clinical pediatric cancer environment. Vital research projects have already been identified. The development of this effort was led by Project Impact's team of advisors, **Dr. Suzanne Baker, PhD** of St. Jude Children's Hospital, **Dr. Maryam Fouladi, MD** of Cincinnati Children's Hospital Medical Center, and **Dr. Roger Packer, MD** of Children's National Medical Center.

New Clinical Trial - National Brain Tumor Society has a unique opportunity to partner with global centers of excellence to augment the work of Project Impact with a new cutting-edge clinical trial supporting precision therapy for pediatric (high-grade glioma) patients. This clinical trial will utilize molecular profiling to identify targeted drugs that will improve patient survival.

Clinical Trial Endpoints, spearheaded by the National Brain Tumor Society, works with the U.S. Food & Drug Administration (FDA) and other key stakeholders in the drug discovery and development process to create and adopt new clinical trial endpoints. This critical work will provide a better system of evaluation and approval of potential brain tumor treatments so patients will have access to new and better treatments – more quickly.

PHILANTHROPY IN ACTION 2014


Sources of Revenue



Events
Individual Giving
In-Kind Contributions
Other*


*Interest & Dividend Income

Donor Designations



Area of Greatest Need
Defeat GBM Research Collaborative
Oligodendroglioma Research Fund
Pediatrics
Other

2015 Goals & Beyond



Pediatrics
Other Programs

Future Goals: Our work in 2015 and beyond relies on the generosity of our community and supporters like you. National Brain Tumor Society's goal is to commit \$4 million over the next two years to directly support pediatric initiatives. We need your help to enhance global collaborations, fund critical research, and develop new clinical trials. **Today, National Brain Tumor Society is committed to directing one-third of its research budget to pediatric specific initiatives.**

2015 SCHEDULE OF EVENTS

| | | | |
|-----------------------------------|--------------------|-----------------------------------|-------------------|
| Orange County Brain Tumor Walk | September 12, 2015 | Boston Brain Tumor Walk | October 25, 2015 |
| Long Island Brain Tumor Walk | September 19, 2015 | Race for Hope - Philadelphia | November 1, 2015 |
| Silicon Valley Brain Tumor Walk | September 26, 2015 | Dallas Ft. Worth Brain Tumor Walk | November 14, 2015 |
| Charlotte Brain Tumor Race | October 10, 2015 | Los Angeles Brain Tumor Walk | November 15, 2015 |
| Annual Summit- Research Symposium | October 15, 2015 | Phoenix Brain Tumor Walk | December 12, 2015 |

SAVE THE DATE! National Gala

The Grey Gala
Boston, MA
October 14, 2015

BOARD OF DIRECTORS

Michael Nathanson, JD, LLM, *Chair*

Chairman, Chief Executive Officer & President, The Colony Group

Cord Schlobohm, DMD, *Vice Chair*

Bethesda Dentist

Michael Corkin, *Treasurer*

Owner, Corkin Insurance Agency

Sarah Durham, *Clerk*

Principal and Founder, Big Duck

Jeffrey Kolodin, *Chairman Emeritus*

Retired Senior Vice President, Smith Barney;
Member of Clear Channel Advisory Board

Kristen Campana, Esq.

Bracewell & Giuliani, LLP

Michael Durbin

President, Institutional Wealth Services
Fidelity Institutional Wealth Services

John Frishkopf

Treasurer & Head of Asset Management
NewStar Financial, Inc.

Richard Genderson

Owner, Schneider's of Capitol Hill

Ken Grey

President, Marshall & Sterling Upstate, Inc.

Sheila Killeen, MBA

Retired, Financial Services Executive

Chandri Navarro, Esq.

Hogan Lovells US, LLP

Susan Pannullo, MD

New York Presbyterian Hospital
Neuro-Oncology Starr 651

Alison Ross, Esq.

Legal Professional

Stephen T. Sadler, JD

Managing Director & Senior Financial Counselor
The Colony Group

Rabbi Eric B. Wisnia

Congregation Beth Chaim

Honorary Board Members

G. Bonnie Feldman

Founding Board Member

Scott Memmott, Esq.

Morgan, Lewis & Bockius LLP

OUR MISSION

National Brain Tumor Society is fiercely committed to **finding better treatments**, and **ultimately a cure**, for people living with a brain tumor today and those who will be diagnosed tomorrow. This means effecting change in the system at all levels. It's time to build on progress and transform tomorrow, today.

Visit www.braintumor.org/takeaction to support our critical work.